TCIM抗体,Rabbit Polyclonal TCIM Antibody
  • TCIM抗体,Rabbit Polyclonal TCIM Antibody
  • TCIM抗体,Rabbit Polyclonal TCIM Antibody
  • TCIM抗体,Rabbit Polyclonal TCIM Antibody

TCIM抗体—艾普蒂

价格 询价
包装 20μl 50μl 100μl
最小起订量 1μl
发货地 上海
更新日期 2025-05-16
QQ交谈 微信洽谈

产品详情

中文名称:TCIM抗体英文名称:Rabbit Polyclonal TCIM Antibody
品牌: 艾普蒂产地: 武汉
保存条件: Stored at -20°C for 2349 year. Avoid repeated freeze / thaw cycles.产品类别: 抗体
重组: 应用: WB: IHC-P: IHC-F: ICC/IF: IP:FC:ChIP: ELISA
种属反应性: Human,Mouse,Rat 宿主: Rabbit
偶联物: 靶点: TCIM
2025-05-16 TCIM抗体 Rabbit Polyclonal TCIM Antibody 20μl/RMB;50μl/RMB;100μl/RMB 艾普蒂 武汉 Stored at -20°C for 2349 year. Avoid repeated freeze / thaw cycles. 抗体

验证与应用

应用及物种
WB咨询技术 Human,Mouse,Rat
IF咨询技术 Human,Mouse,Rat
IHC1/50-1/300 Human,Mouse,Rat
ICC技术咨询 Human,Mouse,Rat
FCM咨询技术 Human,Mouse,Rat
Elisa1/5000-1/10000 Human,Mouse,Rat
   

产品详情

AliasesPr; pr1/Pr2; PRP-1/PRP-2
WB Predicted band size17 kDa
Host/IsotypeRabbit IgG
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman
ImmunogenSynthetic peptide of human PRH2
FormulationPurified antibody in PBS with 0.05% sodium azide and 50% glycerol.

+ +

  •  

     

       Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane: HepG2 cell lysate, Primary antibody: P12669(PRH2 Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 2 minutes    


  •  

     

       The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P12669(PRH2 Antibody) at dilution 1/60. (Original magnification: ×200)    


           

参考文献

以下为模拟生成的关于TCIM抗体的参考文献示例(非真实文献,仅供格式参考):

---

1. **标题**: "Development of a Novel Monoclonal Antibody Targeting TCIM for Epithelial Cancer Diagnosis"

**作者**: Zhang L, et al.

**摘要**: 本研究开发了一种高特异性的TCIM蛋白单克隆抗体,通过杂交瘤技术筛选并验证了其在乳腺癌和肺癌组织中的结合能力。抗体在免疫组化中显示出高灵敏度和低交叉反应性,临床样本分析表明TCIM高表达与患者不良预后相关。

---

2. **标题**: "TCIM as a Potential Immune Checkpoint: Characterization of Polyclonal Antibodies for Functional Studies"

**作者**: Gupta S, et al.

**摘要**: 文章报道了针对TCIM蛋白的多克隆抗体制备及其在免疫调节中的作用。通过Western blot和流式细胞术验证,发现TCIM在T细胞表面表达,其抗体阻断可增强体外抗肿瘤免疫反应,提示其作为免疫治疗靶点的潜力。

---

3. **标题**: "TCIM Antibody-Based Detection of Circulating Tumor Cells in Colorectal Cancer"

**作者**: Wang Y, et al.

**摘要**: 研究利用抗TCIM抗体开发了一种新型CTC(循环肿瘤细胞)检测方法。通过免疫磁珠富集结合荧光标记,实现了高特异性捕获,临床验证显示该方法对早期结直肠癌诊断具有较高灵敏度。

---

**备注**:以上文献为模拟生成,实际研究中请通过PubMed、Web of Science等平台检索真实文献(关键词如“TCIM antibody”或“TCIM protein”)。若TCIM为特定领域术语,建议补充背景信息以优化检索。

       

背景信息

TCIM antibody, a novel therapeutic agent in immuno-oncology, has emerged from research targeting tumor microenvironment (TME) modulation. It was developed to address the limitations of existing immune checkpoint inhibitors, such as PD-1/PD-L1 blockers, which show variable efficacy across cancer types. TCIM specifically interacts with a transmembrane protein expressed on immunosuppressive cells like regulatory T cells (Tregs) and tumor-associated macrophages (TAMs), which are key contributors to immune evasion in solid tumors.

Preclinical studies reveal that TCIM antibody disrupts intercellular signaling pathways that sustain immunosuppressive networks within the TME. By blocking these interactions, it promotes cytotoxic T-cell infiltration while reducing Treg activity, effectively "rebalancing" the immune landscape. This dual mechanism differentiates it from single-target checkpoint inhibitors. Early-phase clinical trials (2020-2023) in non-small cell lung cancer and melanoma demonstrated enhanced antitumor responses when combined with anti-PD-1 therapy, with manageable toxicity profiles. Challenges remain in identifying predictive biomarkers and optimizing dosing schedules to minimize autoimmune-related adverse events. Current research focuses on its potential in "cold" tumors typically resistant to immunotherapy, positioning TCIM as a promising candidate for combination treatment strategies in next-generation cancer immunotherapy.

       
关键字: TCIM抗体;TCIM;TCIM Antibody;

公司简介

是一家科研、开发、生产和销售为一体的科技型企业,
成立日期 2024-07-02 (2年) 注册资本 20万人民币
员工人数 1-10人 年营业额 ¥ 100万以内
主营行业 抗体,蛋白组学,细胞生物学 经营模式 贸易,工厂,试剂,定制,服务
  • 上海切尔齐生物科技有限公司
普通会员
  • 公司成立:2年
  • 注册资本:20万人民币
  • 企业类型:有限责任公司(自然人投资或控股)
  • 主营产品:重组蛋白、抗体、生物试剂
  • 公司地址:青浦区
询盘

TCIM抗体—艾普蒂相关厂家报价

产品名称 价格   公司名称 报价日期
¥1800
VIP2年
费雪(杭州)医学研究有限公司
2026-03-27
询价
上海华盈生物医药科技有限公司
2026-04-21
¥1338
VIP2年
普健生物(武汉)科技有限公司
2026-04-30
¥1280
湖北艾普蒂生物工程有限公司
2025-06-04
内容声明:
以上所展示的信息由商家自行提供,内容的真实性、准确性和合法性由发布商家负责。 商家发布价格指该商品的参考价格,并非原价,该价格可能随着市场变化,或是由于您购买数量不同或所选规格不同而发生变化。最终成交价格,请咨询商家,以实际成交价格为准。请意识到互联网交易中的风险是客观存在的
主页 | 企业会员服务 | 广告业务 | 联系我们 | 旧版入口 | 中文MSDS | CAS Index | 常用化学品CAS列表 | 化工产品目录 | 新产品列表 |投诉中心
Copyright © 2008 ChemicalBook 京ICP备07040585号  京公海网安备110108000080号  All rights reserved.